SEOUL, South Korea,
Nov. 4, 2016 /PRNewswire/
-- Seegene Inc. (096530.KQ) today announced it has entered
into a worldwide collaboration agreement with Hologic (Nasdaq:
HOLX) to develop and supply high multiplex real-time PCR reagents for the Hologic Panther Fusion™
system that is currently in development.
Under the terms of the agreement, Seegene will develop and
manufacture multiplex assays based on DPO™, TOCE™, and MuDT™
technologies for Hologic's next generation molecular diagnostics
platform, the Panther Fusion™ system. Hologic, in turn, will obtain
worldwide commercialization rights to these assays. Financial terms
of the agreement were not disclosed.
Hologic is a leading developer, manufacturer and supplier of
premium diagnostic products, medical imaging systems and surgical
products, with strong positions in women's health. Hologic's
Panther® system is a fully automated sample-to-answer
instrument, which eliminates the need for batch processing and
automates all aspects of nucleic acid testing on a single,
integrated platform. The Fusion expansion module, once
commercialized, will provide laboratory customers a seamless
evolution of their Panther system and allow expanded assay menu
with real-time PCR capabilities in
a single-unit-dose format.
Hologic Diagnostic President Tom
West, said, "We are pleased
to partner with Seegene and incorporate their innovative
technologies with our system. Seegene's multiplex reagents will
enable simultaneous detection and quantification of various target
genes, further broadening the menu of Hologic's Panther Fusion™
system and strengthening its leadership position in the molecular
diagnostic market."
Seegene expands tremendous effort to continually develop and
commercialize innovative high multiplex PCR technologies that enable more accurate
and cost-effective molecular diagnostics. MuDT™ technology provides
perfection of qPCR technology by
simultaneously identifying and quantifying multiple targets in a
single fluorescence channel.
Dr. Jong - Yoon Chun, Founder and
CEO of Seegene, said, "Our
agreement with Hologic represents another meaningful milestone to
Seegene's global expansion initiatives in the molecular diagnostics
market. We expect to accelerate technological standardization in
the MDx market by building up capabilities of assay development
applying on various platforms."
About Seegene
Seegene is the world's leading developer of multiplex molecular
technologies and multiplex clinical molecular diagnostics (M-MoDx).
Seegene's core enabling technologies – DPO™, TOCE™, and MuDT™ - are
the foundation for M-MoDx tests that can simultaneously detect
multiple targets with high sensitivity, specificity and
reproducibility. Seegene's products detect multi-pathogens
with great reliability and throughput, ultimately providing the
most economical basis for saving time, labor and cost. Seegene's
mission is to maintain leadership in molecular diagnostics for
infectious diseases, genetics, pharmacogenetics, and oncology using
innovative proprietary technologies. For more information, please
visit www.seegene.com.
Contact:
Yoon Chung
Tel: 82-2-2240-4082
yjchung7@seegene.com
Alex Baek
Tel: 82-2-2240-4025
mwbaek@seegene.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/seegene-and-hologic-form-worldwide-collaboration-to-develop-high-multiplex-molecular-diagnostic-assays-300357523.html
SOURCE Seegene